Bioserenity
French healthcare company
From Wikipedia, the free encyclopedia
BioSerenity is a medtech company created in 2014 that develops ambulatory medical devices to help diagnose and monitor patients with chronic diseases[3] such as epilepsy.[4] The medical devices are composed of medical sensors, smart clothing or consumables,[5] a smartphone app for Patient Reported Outcome, and a web platform to perform data analysis through Medical Artificial Intelligence[6][7] for detection of digital biomarkers.[8] The company initially focused on Neurology,[9] a domain in which it reported contributing to the diagnosis of 30 000 patients per year.[10] It now also operates in Sleep Disorders and Cardiology.[11] BioSerenity reported it provides pharmaceutical companies with solutions for companion diagnostics.[12]
| Company type | Privately held company |
|---|---|
| Industry | research and development in biotechnology |
| Founded | January 29, 2014 |
| Founder | Pierre-Yves Frouin |
| Headquarters | Paris , France |
Area served | US, France, China |
| Products | Neuronaute, Cardionaute, Cardioskin[1] |
| Services | Neurophy, Cardiophy, Somnophy[2] |
Number of employees | 400 (2019) |
| Website | www |
Company history
BioSerenity was founded in 2014, by Pierre-Yves Frouin. The company was initially hosted at the ICM Institute (Institute du Cerveau et de la Moëlle épinière),[13][14] in Paris, France.
Fund Raising
- June 8, 2015 : The company raised a $4 million seed round with Kurma Partners and IdInvest Partners[15]
- September 20, 2017 : The company raised a $17 million series A round with LBO France, IdInvest Partners and BPI France[16]
- June 18, 2019 : The company raised a $70 million series B round with Dassault Systèmes, IdInvest Partners, LBO France and BPI France[17]
- November 13, 2023 : The company raised a 24M€ series C round with Jolt Capital[18]
Acquisitions
In 2019, BioSerenity announced the acquisition of the American Company SleepMed[19] and Novasom[20]
Development
In 2019, was working with over 200 Hospitals.
In 2020, BioSerenity was one of the five French manufacturers (Savoy, BB Distrib, Celluloses de Brocéliande, Chargeurs) working on the production of sanitary equipment including FFP2 masks at request of the French government.[21]
In 2021, the Neuronaute was used by approximately 30,000 patients per year.[22]
In 2023, the company launched the Icecap, a single use EEG solution[23][24] and its A.I. model for Sleep Disorders with teams from Stanford University.[25][26][27]
In 2025, the company was performing more than 45,000 EEGs (electroencephalograms), 8,000 PSGs (polysomnographies), and 5,000 ECGs (electrocardiograms) each year.[28] The company launched a new EEG A.I. model[29] and signed an agreement to distribute its solutions in the USA through Stratus.[30]
In November 2025, Emmanuel Mougeotte, former CEO of CompuGroup Medical France, became CEO of the company [31] and in January 2026, Pierre-Yves Frouin, founder of BioSerenity concluded his tenure and exited the company.[32]